We are live on ! Find out more
NVS icon

Novartis

905 hedge funds and large institutions have $18.2B invested in Novartis in 2016 Q4 according to their latest regulatory filings, with 121 funds opening new positions, 301 increasing their positions, 355 reducing their positions, and 79 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more first-time investments, than exits

New positions opened: 121 | Existing positions closed: 79

21% more call options, than puts

Call options by funds: $98.8M | Put options by funds: $81.4M

3% more funds holding

Funds holding: 877905 (+28)

0.6% more ownership

Funds ownership: 10.03%10.63% (+0.6%)

2% less capital invested

Capital invested by funds: $18.7B → $18.2B (-$446M)

15% less repeat investments, than reductions

Existing positions increased: 301 | Existing positions reduced: 355

25% less funds holding in top 10

Funds holding in top 10: 2821 (-7)

Holders
905
Holders Change
+28
Holders Change %
+3.19%
% of All Funds
22.58%
Holding in Top 10
21
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-25%
% of All Funds
0.52%
New
121
Increased
301
Reduced
355
Closed
79
Calls
$98.8M
Puts
$81.4M
Net Calls
+$17.4M
Net Calls Change
+$12.4M

NVS Hedge Fund Activity: Q4 2016 in Review

905 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q4 2016, worth a combined $18.2B — down 2.4% from $18.7B a quarter earlier.

Buyers outnumbered sellers: 121 funds opened new NVS positions and 79 closed out — a net gain of 42 holders — while 301 added to existing stakes and 355 trimmed.

The largest buyer was 1832 Asset Management, adding an estimated $180M. The largest seller was Cambiar Investors, exiting entirely with an estimated $176M sold.

  • 905 institutional investors held Novartis (NVS) as of Q4 2016, up from 877 in Q3 2016.
  • Funds reported $18.2B of Novartis stock for Q4 2016, down 2.4% quarter-over-quarter.
  • 121 funds opened new Novartis positions in Q4 2016 and 79 closed out, a net change of +42 holders.
  • The largest Novartis buyer in Q4 2016 was 1832 Asset Management, an estimated $180M added.
  • The largest Novartis seller in Q4 2016 was Cambiar Investors, an estimated $176M sold.

Based on aggregated 13F filings for Q4 2016.